ZYDUSLIFE \u2014 Recent Activity

India's Zydus, Lupin sign deal to co‑market Semaglutide injections

March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to co‑market semaglutide injections in the country ahead of the ingredient's

Click to open →

Zydus Lifesciences Ltd (BOM:532321) Q3 2026 Earnings Call Highlights: Strong Revenue Growth ...

Despite impressive revenue gains, Zydus Lifesciences Ltd faces challenges with increased R&D expenses and market uncertainties.

Click to open →

India's Zydus Life agrees $120 million settlement with Astellas over bladder drug

Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder

Click to open →

India's Zydus Life posts surprise profit rise on strong North American sales

Feb 9 (Reuters) - Indian drugmaker Zydus Lifesciences Ltd reported a third-quarter profit above estimates on Monday, underpinned by new drug launches in North America, its biggest market.

Click to open →

Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch

Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a recently closed manufacturing collaboration with Zydus Lifesciences, the expansion of France’s reimbursed e

Click to open →

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Agenus has provided Zydus with exclusive rights to develop and commercialise BOT/BAL in India and Sri Lanka.

Click to open →

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of its cancer tests in India.

Click to open →

Formycon and Zydus sign exclusive agreement for FYB206 supply

On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.

Click to open →

Zydus Lifesciences Ltd (BOM:532321) Q2 2026 Earnings Call Highlights: Robust Revenue Growth ...

Despite strong financial performance and strategic acquisitions, Zydus faces challenges with increased operating expenses and market uncertainties.

Click to open →

Fortress Biotech Gets US FDA Letter for Deficiencies at Manufacturing Site; Stock Down 30% Premarket

Fortress Biotech (FBIO) and its Cyprium Therapeutics unit said Wednesday that the US Food and Drug A

Click to open →